Navigation Links
Potential Cure for Lymphoma in HIV patients

Stem cell transplants have become the standard of care for patients with relapsed lymphoma, but not for patients who suffer from both this disease and HIV. A new study showing that this treatment is a viable option for select patients with HIV-associated lymphoma will be published in the January 15, 2005, issue of Blood, the official journal of the American Society of Hematology. Because of the immunodeficiency associated with HIV, HIV-positive patients are more likely to develop lymphoma than HIV-negative individuals, and the treatment for their cancer is far less likely to be successful.

Sonali Smith, M.D., Assistant Professor of Medicine at the University of Chicago notes, "The treatment of malignant lymphomas in HIV-infected individuals remains challenging, due to both the high incidence of refractory disease and the high risk of treatment-related complications. The ability of high dose chemotherapy as demonstrated in this pilot study to effectively treat even refractory disease is highly encouraging and certainly warrants further study." Researchers from the City of Hope Cancer Center studied 20 patients (aged 11 to 68) who had HIV and lymphoma, either Hodgkin’s or non-Hodgkin’s. The selected patients had undergone previous standard-dose frontline chemotherapy for their lymphoma, but the majority either failed to achieve a complete remission or had relapsed after an initial remission. The median length of study follow-up was approximately two and a half years, with a range of about six months to six years. All study patients were to undergo autologous stem cell rescue. In an autologous transplant, stem cells are removed from the patient and frozen for later use. The patient receives high-dose chemotherapy to kill any lymphoma in the body, and the autologous stem cells are then infused back into the patient to repopulate the bone marrow wiped out by the chemotherapy. Before the transplant, patients were given one of two conditioning regimens, either high dose chemotherapy alone or in combination with radiation therapy, to destroy the cancerous cells. Most (17 patients versus three) received the chemotherapy-only option. Radiation therapy was selected for patients younger than 55 who had poorer prognostic factors: either the cancer had spread to multiple lymph nodes or the patient had bulky disease (indicated by a cancerous mass greater than 5 ?10 cm). Reversible abnormalities in liver function, a side effect of the intensive treatment, were experienced in a majority of the patients. One patient, the oldest in the study, developed cardiomyopathy (a weakening of the heart) and kidney failure due to treatment toxicities and died a few weeks after the transplant. Opportunistic infections, such as herpes zoster and cytomegalovirus infection, also occurred in a few patients after the transplant, but were managed with appropriate therapy. Throughout the study, all patients were to receive highly active antiretroviral therapy (HAART) to help reduce these opportunistic infections and improve immunodeficiency, however, only nine patients were able to tolerate this treatment for the entire study due to side effects such as nausea and inflammation of the mouth lining. The majority of patients, though, did resume the HAART therapy soon after discharge from the hospital. Although two patients died of relapsed lymphoma a few months after transplant, 17 of the 20 patients (85 percent) are currently alive and in remission. In addition, the underlying HIV infection did not worsen as a result of the transplant and associated treatments. “The results of this study are significant because, despite the use of effective antiviral drugs such as HAART, lymphoma is still a major cause of suffering and death in HIV-infected individuals. It’s important to know that stem cell transplant is an available and highly successful treatment option for these patients,?said Amrita Krishnan, M.D., a staff physician at the City of Hope Cancer Center and l ead author of the study.
'"/>

Source:American Society of Hematology


Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential treatments for neurofibromatosis
3. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
4. Potential Drug Target For Treating Cocaine Abuse Found
5. Potential vaccine developed for deadly leishmaniasis disease
6. Potential heart benefit found in stem cells
7. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
8. Measuring hormone cuts antibiotic use in half in pneumonia patients
9. Doctors closer to using gene analysis to help trauma patients
10. Research shows smoking adds a decade to reproductive age of IVF patients
11. Renewed hope for Parkinsons patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... ... is proud to announce it has become the premiere team-building cooking event company in San ... world, such as Illumina, HP and Qualcomm, and is ranked #1 in its category on ... to its new team building format, a way for teams to not only interact with ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
Breaking Biology Technology: